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The 6th World Congress of Itch,* pre-
viously known as the International 
Workshop for the Study of Itch, marked 
the tenth year of the biennial meet-
ing, which was first held in Singapore 
in 2001. The congress, which was 
organized by Laurent Misery from the 
University of Brest (France), covered a 
comprehensive range of topics, from 
basic science to clinical aspects and 
therapy. The estimated 130 attendees 
comprised researchers and clinicians 
from all over the world, including 
basic scientists, dermatologists, neuro-
scientists, pharmacologists, allergists, 
and internists. This report provides a 
summary of the lectures given during 
the congress and highlights the recent 
advances made in the field.
physiological aspects
The speakers provided an exciting ses-
sion with advances made and updates 
on their research. Ethan Lerner, from 
Massachusetts General Hospital 
(Boston), explained the likely mecha-
nism by which cathepsin S, a cysteine 
protease similar to mucunain in cow-
hage, induces inflammation and itch. 
He showed that cathepsin S induces 
signal transduction by cleaving pro-
tease-activated receptor (PAR)-2 near 
its N-terminus, a mechanism simi-
lar to that of serine proteases. Sarah 
Ross, from the University of Pittsburgh 
(Pennsylvania), presented her find-
ings on the identification of neurons 
that inhibit itch signaling in the spi-
nal cord of mice. These neurons are 
a subset of the inhibitory neurons in 
laminae I and II of the dorsal horn, 
and their development requires a 
novel Bhlhb5/Prdm8 transcriptional 
repressor complex.
Xinzhong Dong, from Johns Hopkins 
University (Baltimore, Maryland), pre-
sented his work on Mas-related G 
protein–coupled receptors (Mrgprs), 
which are present on cutaneous nerves 
and serve as the molecular relay for 
chloroquine-induced itch. He showed 
that application of BAM8-22, an 
endogenous-specific agonist for the 
subtype of Mrgpr present in humans, 
induces an itch that is not relieved by 
an antihistamine. Klas Kullander, from 
Uppsala University (Sweden), spoke 
about their findings on the role of vesic-
ular glutamate transporter 2 (VGLUT2) 
in itch inhibition. He reported that in 
a subpopulation of peripheral sensory 
neurons that transmit thermal pain 
(those expressing the vanilloid recep-
tor 1), VGLUT2-mediated release of the 
neurotransmitter glutamate resulted in 
inhibition of itch signaling. This inhibi-
tion involved both histamine- and non-
histamine-induced itch and probably 
occurred at the level of the spinal cord.
Ferda Cevikbas, from the University 
of California, San Francisco, spoke 
about the spinal cord neuronal recep-
tors involved in itch signaling. Besides 
gastrin-releasing peptide receptor, 
which functions in the pathway spe-
cifically transmitting itch, N-methyl-
d-aspartate glutamate receptor and 
interleukin-31 receptor subunit A 
may also have a role in itch signal-
ing at the central level. Earl Carstens, 
from the University of California, 
Davis, presented a novel mouse model 
of alloknesis (the induction of itch 
through innocuous stimuli). Following 
intradermal injection of histamine into 
the hind limb of C57/BL6 mice, stimu-
lation by von Frey filaments evoked 
scratching bouts. This touch-evoked 
scratching also occurred following 
intradermal injections of other pruri-
togens, namely serotonin and a PAR-4 
agonist, but not with chloroquine and a 
PAR-2 agonist.
Alexandru Papoiu, from Wake Forest 
University (Winston-Salem, North 
Carolina), presented his findings on 
the brain processing of histamine- and 
cowhage-induced itch under various 
chronic pruritic conditions (atopic der-
matitis, psoriasis, and uremic pruritus). 
Compared with healthy individuals, 
significant differences in brain activa-
tion patterns were noted in these dis-
ease states. The activation patterns also 
appeared to vary between the pruritic 
diseases. Matthias Ringkamp, from the 
Johns Hopkins School of Medicine 
(Baltimore, Maryland), presented the 
first study that demonstrates the role 
of cutaneous myelinated nerve fibers 
in itch signaling. Itch is known to be 
transmitted by unmyelinated C nerve 
fibers; using monkeys, Ringkamp found 
that cowhage-induced itch is medi-
ated through both unmyelinated C- and 
myelinated Aδ-nerve fibers.
pathophysiology of chronic  
pruritic diseases
Akio Tanaka, from Hiroshima University 
Graduate School of Medicine (Japan), 
presented the molecular pathology 
of familial primary localized cutane-
ous amyloidosis, a dermatosis that 
is extremely itchy. Neurotrophins 
were not found to be increased in the 
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disease, except for a meteorin-like 
protein, which functions in promot-
ing axonal extension and may be pro-
duced as a result of nerve loss. Kenji 
Takamori, from Juntendo University 
(Tokyo, Japan), presented his research 
on epidermal hyperinnervation in 
atopic dermatitis (AD). He found that 
it is caused by an imbalance of nerve-
elongation factors, specifically nerve 
growth factor, as well as nerve-repul-
sion factors, specifically semaphorin-
3A. Psolaren UVA therapy was shown 
to reduce the hyperinnervation through 
normalizing the levels of these factors. 
In addition, Takamori noted that matrix 
metallo proteinase-2 is involved in the 
penetration of nerve fibers through the 
basement membrane and that sema-
phorin-3A ointment reduced epidermal 
hyperinnervation and scratching in an 
AD mouse model.
Thierry Olivry, from the Center 
for Comparative and Translational 
Research, North Carolina State 
University (Raleigh), presented 
fas cinating research data on AD and 
itch in dogs, which are major issues 
in veterinary medicine. He reported 
numerous similarities in clinical fea-
tures, immunopathogenesis, and 
response to pharma cological treatment 
between human and canine AD. He 
further proposed that canine models of 
AD are well suited for testing medica-
tions designed for use in human AD. 
Martin Steinhoff, from the University of 
California, San Francisco, provided a 
review of the roles of proteases and pro-
teinase-activated receptors in pruritus. 
He also spoke about endothelin-
converting enzyme-1, which prolongs 
cell signaling in dorsal root ganglion 
neurons and acts as a key regulator in 
endothelin-1-induced pruritus.
psychological and  
epidemiological aspects
Jon Anders Halvorsen, from Oslo 
University Hospital (Norway), presented 
his questionnaire-based cross-section-
al study involving 4,744 adolescents. 
The prevalence of itch in the study 
population was 8.8%, and the associ-
ated factors were female gender, lower 
socioeconomic status, psychological 
problems, and a history of atopy. Jörg 
Kupfer, from Justus-Liebig-University 
(Giessen, Germany), presented two 
studies involving the induction of itch 
using audiovisual stimuli in patients 
with AD and healthy volunteers. Itch 
intensity and scratching movements 
were found to be increased when sub-
jects were shown videos of itchy condi-
tions. These parameters were higher in 
patients with AD compared to controls.
Andrea Evers, from Radboud 
University Medical Centre (Nijmegen, 
The Netherlands), presented sev-
eral studies suggesting a relationship 
between stress and itch in chronic skin 
diseases. Increasing evidence indi-
cates that this relationship is particu-
larly significant during periods with 
high daily stressors and when height-
ened stress levels are maintained for 
a long period of time. Markus Kölle, 
from the University of Ulm (Germany), 
presented brain magnetic resonance 
imaging (MRI) findings of patients with 
delusional infestation. He showed that 
the dopaminergic brain regions, such 
as the dorsal striatum (putamen), may 
be macroscopically and/or function-
ally disturbed in the various forms of 
delusional infestation.
Clinical aspects
Jacek Szepietowski, from the Medical 
University of Wroclaw (Poland), pre-
sented a review of drug-induced pru-
ritus, which comprises approximately 
5% of all skin adverse drug reactions. 
Most drugs cause acute pruritus last-
ing less than 6 weeks, but some are 
longer lasting, such as hydroxyethyl 
starch, which is stored in the neurons. 
Christelle LeGall-Ianotto, from the 
University of Brest (France), spoke on 
aquagenic pruritus in polycythemia 
rubra vera, which affects 30 to 50% 
of the patients. Promising etiological 
treatment consists of interferon-α and 
inhibitors of Janus kinase 2, histone 
deacetylase, and mammalian target 
of rapamycin. Symptomatic treatment 
consists of selective serotoninergic 
reuptake inhibitors—in particular, 
paroxetine—and antihistamines.
treatment of itch
Florian Pfab, from the Technical 
University of Munich (Germany), 
presented his studies demonstrating the 
efficacy of acupuncture in inhibiting 
experimentally induced itch in AD 
patients. He showed that acupunc-
ture was more effective in reducing 
allergen-induced itch, administered 
by skin pricks, compared with preven-
tive and sham acupuncture, cetirizine, 
and placebo. A subsequent functional 
MRI study showed that a reduction 
in itch in (abortive) acupuncture was 
associated with diminished activity in 
areas of the brain stimulated by itch: 
the anterior insula, the anterior mid-
dle cingulate cortex, and several areas 
of the striatum.
Sonja Ständer, from University 
Hospital Münster (Germany), sum-
marized the role of substance P in itch 
and presented her experience with the 
use of aprepitant, an antagonist to the 
neurokinin-1 receptor that substance 
P binds to. Aprepitant at 80 mg o.d. 
for 1 week was shown to significantly 
reduce chronic itch of various etiolo-
gies, especially in patients with pru-
rigo nodularis and atopic predisposi-
tion. Alan Fleischer, from Wake Forest 
University (Winston-Salem, North 
Carolina), presented a meta-analysis 
of placebo-controlled trials on the 
efficacy of topical and systemic thera-
pies in reducing itch in AD. There is a 
general paucity of data on the topic, 
with the exception of systemic anti-
histamines, which, despite their wide-
spread use, were clearly shown not to 
have a significant effect.
Gil Yosipovitch, from Wake Forest 
University (Winston-Salem, North 
Carolina), presented his perspectives on 
the treatment of itch. He explained that 
pruritus is a multifactorial disease and 
that with improved understanding of its 
pathological mechanisms, numerous 
targets for future therapies have been 
identified: the G protein receptors (PAR-
2, H4 histamine receptors, and Mrgprs) 
and transient receptor potential vanil-
loid 1, 3, and 4 channels in the periph-
ery; gastrin-related peptide and neuro-
kinin-1 receptors in the spinal cord; and 
the cingulate cortex in the brain.
An interest-group meeting on itch 
questionnaires was held, and research-
ers from Japan, Europe, and the United 
States provided their views on the use 
of various types of questionnaires to 
assess the multidimensional nature of 
itch. It was agreed by all participants 
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that standardizing the methods of eval-
uating itch is of prime importance.
Awards
The Handwerker Prize for young 
researchers, named in honor of the 
famous pain and itch researcher 
Hermann Otto Handwerker from the 
University of Erlangen (Germany), was 
awarded to Hannah Moser, a PhD stu-
dent working with Glenn Giesler at the 
University of Minnesota (Minneapolis). 
She investigated the response of 
trigeminothalamic tract neurons to 
pruritogens in rats and found that there 
is no evidence for an itch-specific 
pathway in the trigeminal system.
The recipient of the Best Poster award 
was Christina Schut, from Justus-Liebig 
University (Geissen, Germany), for her 
study on mental induction of itch. She 
compared itch intensity and scratching 
response between patients with chronic 
urticaria and healthy individuals when 
they were shown videos of crawling 
insects and various skin diseases.
The 7th World Congress on Itch is 
scheduled to take place in Boston, 
Massachusetts, in September 2013. 
It will be organized by Ethan Lerner 
from Harvard University.
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